An Amplified and Overexpressed Gene in Colorectal Cancers
The identification of 26#77 provides a novel basis for the development of diagnostics and therapeutics for colorectal cancer.The utilization of 26#77 gene copy number and RNA and protein levels as a biomarker allows for the facilitation of targeted therapies for colorectal cancer
Diagnosis and treatment of colorectal cancer. Determination of efficacy of a therapeutic regimen to treat colorectal cancer. For the determination of the presence/absence of a colorectal cancer cell in a patient by monitoring the gene copy number or RNA and protein expression levels of 26#77The assays for identification of 26#77 can be used to detect/predict the likelihood of colorectal cancer, estimate the survival from colorectal cancer and/or screen for agents that modulate 26#77 activityProtein products of 26#77 can be used to test characteristics of cancer cells, including cell growth, inhibition, apoptosis, proliferation and transformation26#77-specific nucleic acid or antibody probes can be incorporated into diagnostic kitsCompounds that inhibit 26#77 can be used as potential therapeutics against colorectal cancer
Researchers at the University of California have identified a novel oncogene, 26#77, by virtue of its RNA expression profile in a breast cancer cell line. The 26#77 gene is located on chromosome 20q13.2, a region whose amplification is associated with poor cancer prognosis. They found that 26#77 is amplified and 26#77 RNA and protein are overexpressed in 60% of colorectal cancers. The researchers have used this discovery to develop methods for diagnosing and treating diseases and disorders, such as colorectal cancer, characterized by amplification of the 26#77 gene and/or overexpression of 26#77 gene products. The diagnostics include use of Northern blots, in situ hybridization, and immunoassays to determine the levels of 26#77 RNA and protein in biological samples. Treatment methods include the use of antisense and siRNA to decrease levels of 26#77. Cultured cells expressing 26#77 are also available.
Patent Number: US7537905B2
Application Number: US2003346367A
Inventor: Slamon, Dennis J. | Anderson, Lee A. | Ginther, Charles L.
Priority Date: 15 Jan 2003
Priority Number: US7537905B2
Application Date: 15 Jan 2003
Publication Date: 26 May 2009
IPC Current: G01N0033574 | C12Q000168
US Class: 43500723 | 43500614 | 435006
Assignee Applicant: The Regents of the University of California
Title: Amplified and overexpressed gene in colorectal cancers
Usefulness: Amplified and overexpressed gene in colorectal cancers
Summary: (M1) is useful for determining the presence or absence of colorectal cancer cell in a patient, where the patient is undergoing a therapeutic regime to treat colorectal cancer, or suspected of having colorectal cancer (claimed). (M1) is useful for diagnosing colon cancer and other proliferative disease. (M1) is useful for screening the agents that modulate the subject's 2677 gene product activity, or agents that inhibit cell proliferation.
Novelty: Determining presence or absence of colorectal cancer cell in patient, involves determining level of target protein such as 2677 protein, or target nucleic acid encoding target protein, in biological sample from patient
診斷/治療
癌症/腫瘤
7537905
State Of Development BACKGROUND Chromosome abnormalities are often associated with genetic disorders, degenerative diseases, and cancer. In fact, the deletion or multiplication of copies of whole chromosomes, chromosomal segments, or specific regions of chromosomes are common occurrences in cancer, and can be the cause of some cancers. One such amplified region found in studies of breast and colon cancer cells is on chromosome 20, specifically 20q13.2. Increased copy number of 20q13.2 is found in greater than 25% of cancers of the ovary, colon, head-and-neck, brain, and pancreas. However, it is unknown what gene target(s) is/are responsible for this increase in cancer. Additional Technologies by these Inventors Tech ID/UC Case 10256/2002-341-0 Related Cases 2002-341-0
美國
